Clinical hemodynamic profile of trimazosin in hypertension.
This report describes the clinical hemodynamic response of hypertensive patients to trimazosin. Data were drawn from six different clinical trials involving a total of 171 study patients. Some of the patients were represented in more than one study. These studies range from single-dose experiences, through long-term administration for periods greater than 1 year, to hour-by-hour observation of effects following single doses. These data demonstrate that (1) trimazosin is an effective antihypertensive agent for controlling both systolic and diastolic pressure, (2) its optimum daily dose in monotherapy in this study was at least 600 mg/day, (3) its effects persist without loss of efficacy for more than 1 year, (4) its effects involve a decrease in peripheral vascular resistance without significant cardiac effects, (5) effects on heart rate are small and are seen only mildly in the presence of diuretics in the standing position (being due to the diuretics), (6) reduction of blood pressure during exercise appears to be less than that at rest, and (7) its side effects appear to be minor and are, for the most part, a reflection of its hemodynamic effects.
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005080:Exercise Test; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011187:Posture; D013997:Time Factors
D000959:Antihypertensive Agents; D010879:Piperazines; D006852:Hydrochlorothiazide; C005185:trimazosin